Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.

Image: MarketWatch
ad slot · in-content video 16:9
Coverage
Coverage
- As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.